Company intelligence

Retension Pharmaceuticals

Biotech

Retension Pharmaceuticals profile

written 2026-11-20

Retension Pharmaceuticals (Nasdaq: RTSN) is a clinical-stage company developing RTN-001, an oral PDE-5 inhibitor for uncontrolled and resistant hypertension.

What Retension does

Retension Pharmaceuticals describes itself as a clinical-stage biopharmaceutical company focused on medicines for hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is described as a next-generation, once-daily, oral, small molecule PDE-5 inhibitor designed to lower blood pressure by boosting nitric oxide signaling.[1],[2]

The company says first-generation PDE-5 inhibitors were unable to meaningfully reduce blood pressure. It hypothesizes that this is due to limited distribution into the thicker, smooth muscle cell-rich central arteries. According to the company, RTN-001 was built with a proprietary surface chemistry platform meant to reach those tissues, including the aorta and the heart muscle.[1]

The company's stated strategy is to advance RTN-001 through clinical development in hypertension, study it in other diseases tied to nitric oxide signaling, and explore combinations with approved generic drugs. It also says it will consider partnerships and may expand its pipeline beyond RTN-001.[1]

RTN-001 is an investigational compound and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.[2],[1]

Origins and leadership

Retension says it was founded in 2023 by a leadership team with experience in surface chemistry technologies and small molecule drug discovery. RTN-001 was originally discovered and developed by Surface Logix, Inc., where members of the Retension team led its early development. The company says it holds an exclusive, worldwide, royalty-bearing license to the compound and keeps the clinical data from the nine completed trials run by Surface Logix.[1]

Eric Keller is chief executive. The company's news page lists the appointment of Alison Schecter, M.D., as chief medical officer and Alex Schwartz as chief financial officer. It also lists LeAnne Bloedon as executive vice president of clinical development and operations and Kevin Schutz as vice president of regulatory affairs, along with the formation of a scientific advisory board.[3],[4]

Clinical program

In its Series B release, Retension said RTN-001 had been studied in 243 human subjects, including two Phase 2 studies in patients with hypertension. A later release for its public offering gives the total as 265 enrolled subjects. Both counts come from the company, and it does not explain the difference.[4],[5],[1]

The company said the Phase 2b trial would be multicenter, double-blind, placebo-controlled and randomized, and would enroll approximately 280 patients. Retension said it would work with the Cleveland Clinic Coordinating Center for Clinical Research, and the release quotes Dr. Luke Laffin of the Cleveland Clinic. The company's news page says topline Phase 2b data are expected in the first half of 2027.[4],[3],[5]

Financing and public offering

Retension's news page lists a Series A that it described as oversubscribed, with a headline figure of $10.4 million. A later release announced the close of a $15 million Series B.[3],[4]

The company priced an upsized initial public offering of 3,750,000 shares at $12.00 per share, with expected gross proceeds of $45.0 million, according to its release hosted on BioSpace. The stock trades on the Nasdaq Capital Market under the ticker RTSN. Leerink Partners, Guggenheim Securities and Oppenheimer & Co. were joint bookrunning managers, and Titan Partners was lead manager.[5]

The company said it would use the net proceeds to complete the Phase 2b trial and to prepare for a planned Phase 3 trial, with the remainder for general corporate purposes. Its news page later reported that the October 2026 upsized offering generated $51.75 million in gross proceeds. That figure is higher than the $45.0 million in the pricing release, and the news page summary does not explain the gap.[5],[3],[4]

Is something wrong on this page?

Recent changes

  1. Oct 7, 2026IPO an undisclosed amount SEC
  2. Oct 7, 2026Retension Pharmaceuticals Amends S-1 Again Pulse story

Debt, IPO & other events

not counted in equity raised
DateEventAmountValuationInvestorsSource
Oct 7, 2026ipo——
SEC

Latest Pulse

  1. The IPO Window: Biotech Keeps Pricing, Tech Still WaitsSmall biotech IPOs keep clearing the market while bigger, capital-intensive listings stall: City Therapeutics, TRexBio and Iambic all moved this week while Firmus's $31 billion listing sits withdrawn.→
  2. TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
  3. Retension's $45M IPO Window Closes On ScheduleRetension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.→
  4. City Therapeutics Sets Terms For ~$175M Nasdaq IPOCity Therapeutics set terms for its Nasdaq IPO, offering 9.7 million shares at $17-$19 to raise roughly $175 million, with trading expected to start Friday under the ticker CTY.→
  5. Iambic's Upsized IPO Terms Hint At Real DemandIambic Therapeutics raised its own IPO target from roughly $100 million to $150 million this week, a rare upward revision at a moment when a much larger data-center listing was being withdrawn entirely.→
  6. The VC Read: IPOs Work For Biotech, Not Tech YetOur read: the public market is pricing small, clinical-stage biotech IPOs just fine right now -- it's larger, capital-intensive tech and infrastructure listings like Firmus that still can't clear.→
  7. Firmus's Withdrawn IPO Still Shadows This WeekDays after Nvidia-backed Firmus withdrew its roughly $31 billion-valuation IPO on market-turbulence grounds, two much smaller biotechs, TRex Bio and Retension Pharmaceuticals, priced their own IPOs anyway -- for a combined $161.7 million.→
  8. IPO Pipeline: 9 Filings, Three Pricings This WeekNine new S-1 filings landed in a recent 48-hour stretch, during the same week the IPO pipeline produced three pricings -- Pine Tree Acquisition ($100 million), TRex Bio ($117 million) and Retension Pharmaceuticals ($45 million) -- a gap private markets keep absorbing that the public window still hasn't fully closed.→
  9. Retension Prices Upsized IPO At $12, Raises $45MRetension Pharmaceuticals priced an upsized IPO at $12.00 per share for $45 million in gross proceeds, days after amending its S-1 for a second time, with shares trading on Nasdaq as RTSN.→
  10. TRex Bio Prices IPO At $14, Raises $116.7MTRex Bio priced its IPO at $14.00 per share, the low end of its range, selling 8.33 million shares for about $116.7 million before trading began on Nasdaq as TRXB.→

Coverage Timeline

newest first
  1. Oct 13, 2026IPORetension's $45M IPO Window Closes On Schedule$45M IPO→
  2. Oct 11, 2026IPOFirmus's Withdrawn IPO Still Shadows This Week→
  3. Oct 9, 2026IPORetension Prices Upsized IPO At $12, Raises $45M$45M IPO priced→
  4. Oct 7, 2026IPORetension Pharmaceuticals Amends S-1 Again→
  5. Sep 21, 2026IPOTRex Bio, Retension File S-1s For Nasdaq IPOs→

All Coverage

IPO
Retension's $45M IPO Window Closes On Schedule
IPO$45M IPO

Retension's $45M IPO Window Closes On Schedule

Retension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.

FOLLOW-UP
IPO
Firmus's Withdrawn IPO Still Shadows This Week
Illustration for: Firmus's Withdrawn IPO Still Shadows This Week
IPO

Firmus's Withdrawn IPO Still Shadows This Week

Days after Nvidia-backed Firmus withdrew its roughly $31 billion-valuation IPO on market-turbulence grounds, two much smaller biotechs, TRex Bio and Retension Pharmaceuticals, priced their own IPOs anyway -- for a combined $161.7 million.

FOLLOW-UP
IPO
Retension Prices Upsized IPO At $12, Raises $45M
IPO$45M IPO priced

Retension Prices Upsized IPO At $12, Raises $45M

Retension Pharmaceuticals priced an upsized IPO at $12.00 per share for $45 million in gross proceeds, days after amending its S-1 for a second time, with shares trading on Nasdaq as RTSN.

FOLLOW-UP
IPO
Retension Pharmaceuticals Amends S-1 Again
Illustration for: Retension Pharmaceuticals Amends S-1 Again
IPO

Retension Pharmaceuticals Amends S-1 Again

Retension Pharmaceuticals filed a second S-1/A amendment on Oct. 7, two days after its first amendment, continuing to move its IPO registration through SEC review since Pulse first covered its original filing in September.

FOLLOW-UP
IPO
TRex Bio, Retension File S-1s For Nasdaq IPOs
IPO

TRex Bio, Retension File S-1s For Nasdaq IPOs

TRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.

DEEP DIVE

Value Add Research

Related Companies

Sources & methodologyshow
Where these figures come from
  • SECprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·